# DeLLphi-305 (NCT06211036)

> Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06211036
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer
- Interventions: Tarlatamab; Durvalumab
- Enrollment: 563
- Primary outcome: OS

## Commentary we found

- X threads: 29
- YouTube: 28
- Podcasts: 17

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=dellphi-305-nct06211036

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06211036", "email": "<work email>"}; the inbox owner confirms by the emailed link.